Developer docs
API playgroundTry for free, no card

Search company profiles

Devatis

Full company profile

uuid000vqot

Namestring
Devatis
Legal namestring
Devatis
Websiteurl
devatis.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Devatis is a privately held pharmaceutical manufacturer and distributor operating a portfolio of generic prescription medicines across 12 therapeutic areas — spanning cardiopulmonary, cardiovascular, CNS, dermatology and immunology, digestive system and metabolism, oncology and hematology, respiratory, sensory organs (ophthalmology), and systemic anti-infectives — and distributed across 12 wholly-owned country entities on 4 continents (Oceania, Europe, North America, Latin America, Asia). Products are manufactured in facilities aligned with US FDA and EU GMP standards, with additional compliance under Swissmedic in Switzerland, supporting cross-jurisdictional market access. The group is the international affiliate network of Turkish pharmaceutical manufacturer Deva Holding A.Ş., with founding operations traced to DEVATIS LTD in New Zealand in 2007 and progressive expansion into Germany (2014), USA (2015), Switzerland (2018), Mexico (2019), Australia and Canada (2020), Serbia (2023), Netherlands and Azerbaijan (2024), and the UK and Austria (2025).

The company commercializes through country-specific direct sales teams engaging physicians, specialists, pharmacists, hospitals, and healthcare systems, augmented by distributor and channel partner relationships (e.g., Mexico ophthalmology distribution at Facofest congress) and a digital supply-chain backbone via TraceLink's MINT network linking order capture, warehouse execution, shipment visibility, and invoicing across wholesalers and 3PL providers. Marketing is concentrated on medical congress presence (ASHP Midyear, DCAT Week, ECRM, FAH, SGDV, Swiss Rheumatology, Mexican Ophthalmology Congress), proprietary content (Pharma Pulse magazine in Switzerland), and CEO-led PR in medical and national media. Revenue is generated through one-time pharmaceutical product sales via standard distribution and healthcare procurement channels; pricing is not publicly disclosed and is negotiated bilaterally. No external funding rounds, institutional investors, or public listing have been disclosed.

Deva Holding A.Ş. is identified as the ultimate parent entity, providing manufacturing and capital backing to the country-level subsidiaries. Group leadership is concentrated in Chairman & CEO Philipp D. Haas. Operational scale disclosures are limited — the listed headcount of 1–10 is inconsistent with a 12-country, multi-therapeutic-area operation and likely reflects incomplete firmographic data rather than actual employee count. Disclosed revenue figures are not available in the source material.

Short descriptiontext

Devatis is a privately held pharmaceutical manufacturer and distributor of generic prescription medicines across 12 therapeutic areas, operating through 12 wholly-owned country entities on 4 continents and serving physicians, pharmacists, hospitals, and healthcare systems under US FDA and EU GMP standards.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Clemente, United States
HQ citystring
San Clemente
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices12 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prescription pharmaceuticals, pharmaceutical manufacturing, generic medicines, therapeutic products, pharmaceutical distribution
Industry2 codes
PRIMARYCRAOAHAA
Prescription Pharmaceutical (Rx) Wholesale Distribution
SECONDARYHLAIAJAM
Direct-to-Provider / Clinic Buy-and-Bill Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals Manufacturing
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Devatis generates revenue through the sale of prescription pharmaceutical products across 12 therapeutic areas. Products are manufactured in FDA and GMP-compliant facilities and distributed through direct sales teams and channel partners across global markets.

devatis.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Devatis manufactures and distributes a broad portfolio of prescription pharmaceutical products across 12 therapeutic areas—including Cardiovascular System, Central Nervous System, Dermatology and Immunology, Digestive System and Metabolism, Oncology and Hematology, Respiratory System, Sensory Organs (Ophthalmology), and Systemic Anti-Infectives—for healthcare professionals, hospitals, and pharmacy chains across 12 countries. Products are produced in facilities aligned with US FDA and EU GMP standards and delivered through direct sales teams and channel partners.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Devatis is a pharmaceutical company that operates as a single unified product offering—a broad portfolio of prescription medicines distributed across 12 therapeutic areas and 12 countries. The portfolio spans Cardiovascular, Central Nervous System, Dermatology and Immunology, Digestive System and Metabolism, Oncology and Hematology, Respiratory, Ophthalmology (Sensory Organs), Systemic Anti-Infectives, and other therapeutic areas. Products are manufactured in US FDA and EU GMP-compliant facilities, ensuring consistent quality and safety. The company also publishes Pharma Pulse, a magazine distributed to healthcare professionals in Switzerland.

Product and service2 records
1Pharmaceutical Products Portfolio
CategoryPrescription Pharmaceuticals
Description

Broad portfolio of prescription medicines across 12 therapeutic areas including Cardiovascular System, Central Nervous System, Dermatology and Immunology, Digestive System and Metabolism, Oncology and Hematology, Respiratory System, Sensory Organs (Ophthalmology), Systemic Anti-Infectives, and other areas. Manufactured in facilities aligned with US FDA and EU GMP standards and sold to healthcare professionals, hospitals, and pharmacy chains across 12 countries.

2Mexico's First Fusidic Acid Product
CategoryOphthalmology Pharmaceuticals
Description

A fusidic acid pharmaceutical product introduced by Devatis in Mexico as the first of its kind in the country, targeted at the ophthalmology therapeutic area and launched at the Facofest congress for ophthalmology professionals.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-20
Description

Devatis has gone live on TraceLink's Multienterprise Information Network Tower (MINT) to digitize its end-to-end order-to-cash operations. This centralized network model replaces fragmented point-to-point EDI integrations, linking order capture, warehouse execution, shipment visibility, invoicing, and financial reconciliation across trading partners including wholesalers and 3PL providers. The implementation reduces new partner onboarding timelines from months to as little as three days and establishes the data foundation required for future AI agent-driven automation in supply chain monitoring.

Recent move15 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Canadian-headquartered generic pharmaceutical manufacturer with vertically integrated operations and international reach; comparable to Devatis in manufacturing integration and broad generic portfolio across multiple therapeutic areas.

TypeDirect peer
Description

Global integrated pharmaceutical company offering generics, biosimilars, and APIs across multiple therapeutic areas with strong presence in North America, Europe, and emerging markets; matches Devatis's international, vertically integrated generic pharma profile.

TypeDirect peer
Description

German-headquartered generic pharmaceutical company with a broad European and international footprint across multiple therapeutic areas, very similar profile to Devatis's vertical integration, multi-country presence, and focus on off-patent molecules.

TypeDirect peer
Description

India-based global pharmaceutical company with a generics portfolio spanning multiple therapeutic areas and a presence in the US, Europe, and emerging markets; directly comparable in business model and international distribution footprint.

TypeBroad incumbent
Description

Global pharmaceutical powerhouse formed from Mylan and Upjohn, offering an extensive generic and branded portfolio across virtually all therapeutic areas; significantly larger than Devatis but competes in the same generic distribution channels worldwide.

TypeDirect peer
Description

Indian-headquartered global generic pharmaceutical manufacturer with extensive international distribution; directly comparable to Devatis in product breadth, vertical integration, and multi-country commercial presence.

TypeDirect peer
Description

Multinational generic and specialty pharmaceutical manufacturer with strong distribution across MENA, Europe, and North America; comparable to Devatis in product breadth, geographic diversification, and FDA/EU GMP manufacturing.

TypeBroad incumbent
Description

World's largest generic pharmaceutical manufacturer with operations in nearly every country and a portfolio spanning virtually every therapeutic area; a much larger incumbent competing in the same generic distribution channels as Devatis.

TypeDirect peer
Description

Privately-held global generic pharmaceutical company with operations across the US, Europe, and Asia; comparable to Devatis in product breadth, multi-country footprint, and vertically integrated generics distribution model.

TypeDirect peer
Description

Indian-headquartered global pharmaceutical company with strong US presence and broad generic portfolio across therapeutic areas; comparable to Devatis in international distribution model and generic focus.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries12 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Devatis

Generic Pharmaceuticals Manufacturingdevatis.com

Devatis is a privately held pharmaceutical manufacturer and distributor of generic prescription medicines across 12 therapeutic areas, operating through 12 wholly-owned country entities on 4 continents and serving physicians, pharmacists, hospitals, and healthcare systems under US FDA and EU GMP standards.

What Devatis does

Devatis is a privately held pharmaceutical manufacturer and distributor operating a portfolio of generic prescription medicines across 12 therapeutic areas — spanning cardiopulmonary, cardiovascular, CNS, dermatology and immunology, digestive system and metabolism, oncology and hematology, respiratory, sensory organs (ophthalmology), and systemic anti-infectives — and distributed across 12 wholly-owned country entities on 4 continents (Oceania, Europe, North America, Latin America, Asia). Products are manufactured in facilities aligned with US FDA and EU GMP standards, with additional compliance under Swissmedic in Switzerland, supporting cross-jurisdictional market access. The group is the international affiliate network of Turkish pharmaceutical manufacturer Deva Holding A.Ş., with founding operations traced to DEVATIS LTD in New Zealand in 2007 and progressive expansion into Germany (2014), USA (2015), Switzerland (2018), Mexico (2019), Australia and Canada (2020), Serbia (2023), Netherlands and Azerbaijan (2024), and the UK and Austria (2025).

The company commercializes through country-specific direct sales teams engaging physicians, specialists, pharmacists, hospitals, and healthcare systems, augmented by distributor and channel partner relationships (e.g., Mexico ophthalmology distribution at Facofest congress) and a digital supply-chain backbone via TraceLink's MINT network linking order capture, warehouse execution, shipment visibility, and invoicing across wholesalers and 3PL providers. Marketing is concentrated on medical congress presence (ASHP Midyear, DCAT Week, ECRM, FAH, SGDV, Swiss Rheumatology, Mexican Ophthalmology Congress), proprietary content (Pharma Pulse magazine in Switzerland), and CEO-led PR in medical and national media. Revenue is generated through one-time pharmaceutical product sales via standard distribution and healthcare procurement channels; pricing is not publicly disclosed and is negotiated bilaterally. No external funding rounds, institutional investors, or public listing have been disclosed.

Deva Holding A.Ş. is identified as the ultimate parent entity, providing manufacturing and capital backing to the country-level subsidiaries. Group leadership is concentrated in Chairman & CEO Philipp D. Haas. Operational scale disclosures are limited — the listed headcount of 1–10 is inconsistent with a 12-country, multi-therapeutic-area operation and likely reflects incomplete firmographic data rather than actual employee count. Disclosed revenue figures are not available in the source material.

Devatis firmographics

Firmographics
Name
Devatis
Legal name
Devatis
Website
https://devatis.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
1–10 employees
Short description
Devatis is a privately held pharmaceutical manufacturer and distributor of generic prescription medicines across 12 therapeutic areas, operating through 12 wholly-owned country entities on 4 continents and serving physicians, pharmacists, hospitals, and healthcare systems under US FDA and EU GMP standards.
Ownership category
akta.pro rank

Devatis industry classification

Industry
Product category
Generic Pharmaceuticals Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYCRAOAHAA
Prescription Pharmaceutical (Rx) Wholesale Distribution
SECONDARYHLAIAJAM
Direct-to-Provider / Clinic Buy-and-Bill Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Prescription pharmaceuticals
  • Pharmaceutical manufacturing
  • Generic medicines
  • Therapeutic products
  • Pharmaceutical distribution

Where Devatis is headquartered

Location

Headquarters

HQ city
San Clemente
HQ country
United States
HQ region
North America

Offices12 records

Markets served

Devatis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Devatis generates revenue through the sale of prescription pharmaceutical products across 12 therapeutic areas. Products are manufactured in FDA and GMP-compliant facilities and distributed through direct sales teams and channel partners across global markets.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Devatis product offering

Product offering

Core offering

Devatis manufactures and distributes a broad portfolio of prescription pharmaceutical products across 12 therapeutic areas—including Cardiovascular System, Central Nervous System, Dermatology and Immunology, Digestive System and Metabolism, Oncology and Hematology, Respiratory System, Sensory Organs (Ophthalmology), and Systemic Anti-Infectives—for healthcare professionals, hospitals, and pharmacy chains across 12 countries. Products are produced in facilities aligned with US FDA and EU GMP standards and delivered through direct sales teams and channel partners.

Product overview

Devatis is a pharmaceutical company that operates as a single unified product offering—a broad portfolio of prescription medicines distributed across 12 therapeutic areas and 12 countries. The portfolio spans Cardiovascular, Central Nervous System, Dermatology and Immunology, Digestive System and Metabolism, Oncology and Hematology, Respiratory, Ophthalmology (Sensory Organs), Systemic Anti-Infectives, and other therapeutic areas. Products are manufactured in US FDA and EU GMP-compliant facilities, ensuring consistent quality and safety. The company also publishes Pharma Pulse, a magazine distributed to healthcare professionals in Switzerland.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharmaceutical Products Portfolio Broad portfolio of prescription medicines across 12 therapeutic areas including Cardiovascular System, Central Nervous System, Dermatology and Immunology, Digestive System and Metabolism, Oncology and Hematology, Respiratory System, Sensory Organs (Ophthalmology), Systemic Anti-Infectives, and other areas. Manufactured in facilities aligned with US FDA and EU GMP standards and sold to healthcare professionals, hospitals, and pharmacy chains across 12 countries.
  • Mexico's First Fusidic Acid Product A fusidic acid pharmaceutical product introduced by Devatis in Mexico as the first of its kind in the country, targeted at the ophthalmology therapeutic area and launched at the Facofest congress for ophthalmology professionals.

Companies that use Devatis

Customer profile

Segments3 records

Ideal customer profiles2 records

Devatis technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Devatis partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • TraceLinkcoreTechnology or Integration · 20 April 2026Devatis has gone live on TraceLink's Multienterprise Information Network Tower (MINT) to digitize its end-to-end order-to-cash operations. This centralized network model replaces fragmented point-to-point EDI integrations, linking order capture, warehouse execution, shipment visibility, invoicing, and financial reconciliation across trading partners including wholesalers and 3PL providers. The implementation reduces new partner onboarding timelines from months to as little as three days and establishes the data foundation required for future AI agent-driven automation in supply chain monitoring.

Scale indicators3 records

Recent moves15 records

Expansion highlights6 records

Devatis competitors and assessment

Company assessment

Direct peers

  • Apotex: Canadian-headquartered generic pharmaceutical manufacturer with vertically integrated operations and international reach; comparable to Devatis in manufacturing integration and broad generic portfolio across multiple therapeutic areas.
  • Dr. Reddy's Laboratories: Global integrated pharmaceutical company offering generics, biosimilars, and APIs across multiple therapeutic areas with strong presence in North America, Europe, and emerging markets; matches Devatis's international, vertically integrated generic pharma profile.
  • Stada Arzneimittel: German-headquartered generic pharmaceutical company with a broad European and international footprint across multiple therapeutic areas, very similar profile to Devatis's vertical integration, multi-country presence, and focus on off-patent molecules.
  • Glenmark Pharmaceuticals: India-based global pharmaceutical company with a generics portfolio spanning multiple therapeutic areas and a presence in the US, Europe, and emerging markets; directly comparable in business model and international distribution footprint.
  • Aurobindo Pharma: Indian-headquartered global generic pharmaceutical manufacturer with extensive international distribution; directly comparable to Devatis in product breadth, vertical integration, and multi-country commercial presence.
  • Hikma Pharmaceuticals: Multinational generic and specialty pharmaceutical manufacturer with strong distribution across MENA, Europe, and North America; comparable to Devatis in product breadth, geographic diversification, and FDA/EU GMP manufacturing.
  • Alvogen: Privately-held global generic pharmaceutical company with operations across the US, Europe, and Asia; comparable to Devatis in product breadth, multi-country footprint, and vertically integrated generics distribution model.
  • Lupin Pharmaceuticals: Indian-headquartered global pharmaceutical company with strong US presence and broad generic portfolio across therapeutic areas; comparable to Devatis in international distribution model and generic focus.

Broad incumbents

  • Viatris: Global pharmaceutical powerhouse formed from Mylan and Upjohn, offering an extensive generic and branded portfolio across virtually all therapeutic areas; significantly larger than Devatis but competes in the same generic distribution channels worldwide.
  • Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with operations in nearly every country and a portfolio spanning virtually every therapeutic area; a much larger incumbent competing in the same generic distribution channels as Devatis.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Devatis social profiles

Digital presence

Devatis compliance and trust

Trust signal

Compliance5 records

Devatis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Devatis leadership team

Management profile

Number of profiles

Profiles1 record

Devatis subsidiaries and ownership

Company hierarchy

Subsidiaries12 records

Devatis funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Devatis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Devatis

What does Devatis do?

Devatis manufactures and distributes a broad portfolio of prescription pharmaceutical products across 12 therapeutic areas—including Cardiovascular System, Central Nervous System, Dermatology and Immunology, Digestive System and Metabolism, Oncology and Hematology, Respiratory System, Sensory Organs (Ophthalmology), and Systemic Anti-Infectives—for healthcare professionals, hospitals, and pharmacy chains across 12 countries. Products are produced in facilities aligned with US FDA and EU GMP standards and delivered through direct sales teams and channel partners.

Is Devatis a public or private company?

Devatis is a private company. It is classified as corporate owned and is currently operating.

When was Devatis founded?

Devatis was founded in 2007. It employs 1 to 10 people.

Where is Devatis based?

Devatis is headquartered in San Clemente, United States, in the North America region.

How does Devatis make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Devatis's main competitors?

Direct peers on record are Apotex, Dr. Reddy's Laboratories, Stada Arzneimittel, Glenmark Pharmaceuticals, Aurobindo Pharma, Hikma Pharmaceuticals, Alvogen and Lupin Pharmaceuticals. Broad incumbents are Viatris and Teva Pharmaceutical Industries.

Does Devatis have an API?

No public API is recorded for Devatis.

What industry is Devatis in?

Devatis's product category is Generic Pharmaceuticals Manufacturing. Its primary akta.pro industry code is CRAOAHAA, Prescription Pharmaceutical (Rx) Wholesale Distribution, with a secondary code of HLAIAJAM, Direct-to-Provider / Clinic Buy-and-Bill Distributors. Its NAICS code is 325412 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals